Pioglitazone (Actos) for Insulin Resistance & Type 2 Diabetes — Weight & Metabolism
PPAR-gamma agonist that addresses root-cause insulin resistance with proven benefits for NAFLD/NASH and cardiovascular risk reduction in the PROactive trial.
Overview
Pioglitazone is the only thiazolidinedione (TZD) in common clinical use, acting as a PPAR-gamma agonist to improve insulin sensitivity in adipose tissue, muscle, and liver. It addresses the root cause of insulin resistance rather than treating symptoms. HbA1c reduction of 0.9-1.5% as monotherapy (1.37% with 30mg in RCTs; PMID: 11491207). The PROactive trial (n=5,238) showed a secondary endpoint reduction of 16% in all-cause mortality, MI, and stroke. Unique among diabetes drugs for proven NAFLD/NASH benefit: reduces hepatic steatosis, inflammation, and fibrosis. Durable glycemic control (slower secondary failure vs sulfonylureas). Limitations include weight gain (2-4kg), fluid retention, and bone fracture risk. PMID: 11491207, 16214598, 30948779.
Indications
- Type 2 diabetes mellitus with prominent insulin resistance
- Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in T2DM
- Metabolic syndrome with multiple insulin resistance-related features
- Add-on to metformin when addressing insulin resistance is the priority
- Prediabetes prevention in high-risk individuals (off-label; ACT NOW trial)
Mechanism of Action
Dysfunctional adipose tissue releases excess free fatty acids and inflammatory cytokines, impairing insulin signaling in muscle, liver, and beta-cells
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Pioglitazone (Actos) | 15 mg | Once daily | Starting dose; recommended in patients at higher HF/edema risk |
| Pioglitazone (Actos) | 30 mg | Once daily | Standard maintenance dose; HbA1c -1.37% in monotherapy trials |
| Pioglitazone (Actos) | 45 mg | Once daily | Maximum dose; modest additional benefit; more edema/weight gain |
Safety & Contraindications
- Fluid retention and edema: occurs in 5-15% of patients; worse when combined with insulin; contraindicated in NYHA Class III-IV heart failure
- Weight gain of 2-4kg expected (primarily subcutaneous adipose redistribution and fluid retention)
- Bone fracture risk: increased in postmenopausal women (distal extremities); use caution in osteoporosis
- FDA black box warning for heart failure: do not use in NYHA Class III-IV; monitor for symptoms
- Possible bladder cancer risk (controversial): slight signal in some epidemiological studies; not confirmed in meta-analyses
- Improvement in insulin sensitivity is slow-onset: full effect requires 8-12 weeks of therapy